{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:08:41Z","timestamp":1769155721500,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10792-021-02145-w","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:03:47Z","timestamp":1641513827000},"page":"1545-1552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Low-dose ranibizumab administration in retinopathy of prematurity"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0819-915X","authenticated-orcid":false,"given":"Levent","family":"T\u00f6k","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00fctfi","family":"Seyrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d6zlem","family":"Yal\u00e7\u0131n T\u00f6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"issue":"7","key":"2145_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 123(7):991\u2013999. https:\/\/doi.org\/10.1001\/archopht.123.7.991","journal-title":"Arch Ophthalmol"},{"key":"2145_CR2","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1097\/01.iae.0000244285.79004.e6","volume":"26","author":"A Kychenthal","year":"2006","unstructured":"Kychenthal A, Dorta P, Katz X (2006) Zone I retinopathy of prematurity: clinical characteristics and treatment outcomes. Retina 26:S11\u2013S15. https:\/\/doi.org\/10.1097\/01.iae.0000244285.79004.e6","journal-title":"Retina"},{"key":"2145_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ophtha.2009.01.038","volume":"116","author":"T Yokoi","year":"2009","unstructured":"Yokoi T, Hiraoka M, Miyamoto M, Yokoi T, Kobayashi Y, Nishina S, Azuma N (2009) Vascular abnormalities in aggressive posterior retinopathy of prematurity detected by fluorescein angiography. Ophthalmology 116:1377\u20131382. https:\/\/doi.org\/10.1016\/j.ophtha.2009.01.038","journal-title":"Ophthalmology"},{"key":"2145_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cct.2004.03.003","volume":"25","author":"RJ Hardy","year":"2004","unstructured":"Hardy RJ, Good WV, Dobson V, Palmer EA, Phelps DL, Quintos M, Tung B (2004) Early Treatment for retinopathy of prematurity cooperative group. Multicenter trial of early treatment for retinopathy of prematurity: study design. Control Clin Trials 25:311\u2013325. https:\/\/doi.org\/10.1016\/j.cct.2004.03.003","journal-title":"Control Clin Trials"},{"key":"2145_CR5","first-page":"290","volume":"37","author":"J Stone","year":"1996","unstructured":"Stone J, Chan-Ling T, Pe\u2019er J, Itin A, Gnessin H, Keshet E (1996) Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 37:290\u2013299","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"2145_CR6","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archopht.1988.01060130509025","volume":"106","author":"W Tasman","year":"1988","unstructured":"Tasman W (1988) Multicenter trial of cryotherapy for retinopathy of prematurity preliminary results. Cryotherapy for retinopathy of prematurity cooperative group. Arch Ophthalmol 106(4):471\u2013479. https:\/\/doi.org\/10.1001\/archopht.1988.01060130509025","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"2145_CR7","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1001\/archopht.121.12.1769","volume":"121","author":"AR Fielder","year":"2003","unstructured":"Fielder AR (2003) Preliminary results of treatment of eyes with high-risk prethreshold retinopathy of prematurity in the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1769\u20131771. https:\/\/doi.org\/10.1001\/archopht.121.12.1769","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2145_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ajo.2006.02.018","volume":"142","author":"JT Flynn","year":"2006","unstructured":"Flynn JT, Chan-Ling T (2006) Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease. Am J Ophthalmol 142(1):46\u201359. https:\/\/doi.org\/10.1016\/j.ajo.2006.02.018","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2145_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","volume":"81","author":"M O\u2019Keefe","year":"2003","unstructured":"O\u2019Keefe M, Lanigan B, Long VW (2003) Outcome of zone 1 retinopathy of prematurity. Acta Ophthalmol Scand 81(6):614\u2013616. https:\/\/doi.org\/10.1111\/j.1395-3907.2003.00171.x","journal-title":"Acta Ophthalmol Scand"},{"issue":"6","key":"2145_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1067\/mpa.2000.107904","volume":"4","author":"X Katz","year":"2000","unstructured":"Katz X, Kychenthal A, Dorta P (2000) Zone I retinopathy of prematurity. J AAPOS 4(6):373\u2013376. https:\/\/doi.org\/10.1067\/mpa.2000.107904","journal-title":"J AAPOS"},{"issue":"1","key":"2145_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ajo.2012.07.012","volume":"155","author":"G Sanghi","year":"2013","unstructured":"Sanghi G, Dogra MR, Katoch D, Gupta A (2013) Aggressive posterior retinopathy of prematurity: risk factors for retinal detachment despite confluent laser photocoagulation. Am J Ophthalmol 155(1):159\u2013164. https:\/\/doi.org\/10.1016\/j.ajo.2012.07.012","journal-title":"Am J Ophthalmol"},{"issue":"4 suppl","key":"2145_CR12","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/IAE.0b013e3181cb6151","volume":"30","author":"KA Drenser","year":"2010","unstructured":"Drenser KA, Trese MT, Capone A Jr (2010) Aggressive posterior retinopathy of prematurity. Retina 30(4 suppl):S37\u2013S40. https:\/\/doi.org\/10.1097\/IAE.0b013e3181cb6151","journal-title":"Retina"},{"issue":"7","key":"2145_CR13","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ (2011) BEATROP cooperative group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"issue":"4","key":"2145_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"W-C Wu","year":"2015","unstructured":"Wu W-C, Lien R, Liao P-J, Wang N-K, Chen Y-P, Chao A-N, Chen K-J, Chen T-L, Hwang Y-S, Lai C-C (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133(4):391\u2013397. https:\/\/doi.org\/10.1001\/jamaophthalmol.2014.5373","journal-title":"JAMA Ophthalmol"},{"issue":"7","key":"2145_CR15","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.18240\/ijo.2017.07.08","volume":"10","author":"T Cakmak Argun","year":"2017","unstructured":"Cakmak Argun T, Yalcin Tok O, Tok L, Yilmaz G, Meric Yilmaz F, Gunes A, Argun M, Butuner O (2017) Transfer of single dose of intravitreal injection of ranibizumab and bevacizumab into milk of sheep. Int J Ophthalmol 10(7):1069\u20131075. https:\/\/doi.org\/10.18240\/ijo.2017.07.08","journal-title":"Int J Ophthalmol"},{"issue":"4","key":"2145_CR16","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/IAE.0000000000000578","volume":"35","author":"RK Wong","year":"2015","unstructured":"Wong RK, Hubschman S, Tsui I (2015) Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 35(4):675\u2013680. https:\/\/doi.org\/10.1097\/IAE.0000000000000578","journal-title":"Retina"},{"key":"2145_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12886-015-0001-7","volume":"15","author":"MN Menke","year":"2015","unstructured":"Menke MN, Framme C, Nelle M, Berger MR, Sturm V, Wolf S (2015) Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease. BMC Ophthalmol 15:20. https:\/\/doi.org\/10.1186\/s12886-015-0001-7","journal-title":"BMC Ophthalmol"},{"issue":"4","key":"2145_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1097\/IAE.0000000000000380","volume":"35","author":"SN Chen","year":"2015","unstructured":"Chen SN, Lian I, Hwang YC, Chen YH, Chang YC, Lee KH et al (2015) Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab. Retina 35(4):667\u2013674. https:\/\/doi.org\/10.1097\/IAE.0000000000000380","journal-title":"Retina"},{"issue":"7","key":"2145_CR19","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1136\/bjophthalmol-2012-302276","volume":"97","author":"MA Castellanos","year":"2013","unstructured":"Castellanos MA, Schwartz S, Garc\u00eda-Aguirre G, Quiroz-Mercado H (2013) Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 97(7):816\u2013819. https:\/\/doi.org\/10.1136\/bjophthalmol-2012-302276","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"2145_CR20","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3928\/23258160-20150422-05","volume":"46","author":"CR Baumal","year":"2015","unstructured":"Baumal CR, Goldberg RA, Fein JG (2015) Primary intravitreal ranibizumab for high-risk retinopathy of prematurity. Ophthalmic Surg Lasers Imaging Retina 46(4):432\u2013438. https:\/\/doi.org\/10.3928\/23258160-20150422-05","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"6","key":"2145_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jamaophthalmol.2017.1055","volume":"135","author":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME, Kong L, Holmes JM; Pediatric Eye Disease Investigator Group (PEDIG)","year":"2017","unstructured":"Wallace DK, Kraker RT, Freedman SF, Crouch ER, Hutchinson AK, Bhatt AR, Rogers DL, Yang MB, Haider KM, VanderVeen DK, Siatkowski RM, Dean TW, Beck RW, Repka MX, Smith LE, Good WV, Hartnett ME, Kong L, Holmes JM; Pediatric Eye Disease Investigator Group (PEDIG) (2017) Assessment of lower doses of intravitreous bevacizumab for retinopathy of prematurity: a phase 1 dosing study. JAMA Ophthalmol 135(6):654\u2013656. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1055","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"2145_CR22","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.101113998","volume":"98","author":"A Hellstrom","year":"2001","unstructured":"Hellstrom A, Perruzzi C, Ju M et al (2001) Low IGF-I suppresses VEGF survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 98(10):5804\u20135808. https:\/\/doi.org\/10.1073\/pnas.101113998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"suppl A","key":"2145_CR23","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.1016\/j.ghir.2004.03.030","volume":"14","author":"LE Smith","year":"2004","unstructured":"Smith LE (2004) Pathogenesis of retinopathy of prematurity. Growth Horm IGF Res 14(suppl A):S140\u2013S144. https:\/\/doi.org\/10.1016\/j.ghir.2004.03.030","journal-title":"Growth Horm IGF Res"},{"issue":"437","key":"2145_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1651-2227.2002.tb00157.x","volume":"91","author":"LE Smith","year":"2002","unstructured":"Smith LE (2002) Pathogenesis of retinopathy of prematurity. Acta Paediatr Suppl 91(437):26\u201328. https:\/\/doi.org\/10.1111\/j.1651-2227.2002.tb00157.x","journal-title":"Acta Paediatr Suppl"},{"issue":"8","key":"2145_CR25","doi-asserted-by":"publisher","first-page":"e1004","DOI":"10.1111\/aos.14460","volume":"98","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Zhu X, Linghu D, Liang J (2020) Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity. Acta Ophthalmol 98(8):e1004\u2013e1008. https:\/\/doi.org\/10.1111\/aos.14460","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2145_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5935\/0004-2749.20170009","volume":"80","author":"EA Sukgen","year":"2017","unstructured":"Sukgen EA, Ko\u00e7luk Y (2017) The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity. Arq Bras Oftalmol 80(1):30\u201334. https:\/\/doi.org\/10.5935\/0004-2749.20170009","journal-title":"Arq Bras Oftalmol"},{"issue":"6","key":"2145_CR27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.4103\/ijo.IJO_708_18","volume":"67","author":"V Vedantham","year":"2019","unstructured":"Vedantham V (2019) Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity. Indian J Ophthalmol 67(6):884\u2013888. https:\/\/doi.org\/10.4103\/ijo.IJO_708_18","journal-title":"Indian J Ophthalmol"},{"issue":"8","key":"2145_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.9.8.43","volume":"9","author":"M Fidler","year":"2020","unstructured":"Fidler M, Fleck BW, Stahl A, Marlow N, Chastain JE, Li J, Lepore D, Reynolds JD, Chiang MF, Fielder AR, Rainbow study group\u2020 (2020) Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Technol 9(8):43. https:\/\/doi.org\/10.1167\/tvst.9.8.43","journal-title":"Transl Vis Sci Technol"},{"issue":"3","key":"2145_CR29","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","volume":"54","author":"L Xu","year":"2013","unstructured":"Xu L, Lu T, Tuomi L, Jumbe N, Lu J, Eppler S, Kuebler P, Damico-Beyer LA, Joshi A (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54(3):1616\u20131624. https:\/\/doi.org\/10.1167\/iovs.12-10260","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"2145_CR30","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","volume":"121","author":"D Lepore","year":"2014","unstructured":"Lepore D, Quinn GE, Molle F, Baldascino A, Orazi L, Sammartino M, Purcaro V, Giannantonio C, Papacci P, Romagnoli C (2014) Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings. Ophthalmology 121(11):2212\u20132219. https:\/\/doi.org\/10.1016\/j.ophtha.2014.05.015","journal-title":"Ophthalmology"},{"issue":"4","key":"2145_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/bjophthalmol-2013-304109","volume":"98","author":"SG Tahija","year":"2014","unstructured":"Tahija SG, Hersetyati R, Lam GC, Kusaka S, McMenamin PG (2014) Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98(4):507\u2013512. https:\/\/doi.org\/10.1136\/bjophthalmol-2013-304109","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2145_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamapediatrics.2017.4838","volume":"172","author":"A Stahl","year":"2018","unstructured":"Stahl A, Krohne TU, Eter N, Oberacher-Velten I, Guthoff R, Meltendorf S, Ehrt O, Aisenbrey S, Roider J, Gerding H, Jandeck C, Smith LEH, Walz JM (2018) Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity (CARE-ROP) study group. Comparing alternative ranibizumab dosages for safety and efficacy in retinopathy of prematurity: a randomized clinical trial. JAMA Pediatr 1 172(3):278\u2013286. https:\/\/doi.org\/10.1001\/jamapediatrics.2017.4838","journal-title":"JAMA Pediatr 1"},{"issue":"2","key":"2145_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153(2):327\u2013333. https:\/\/doi.org\/10.1016\/j.ajo.2011.07.005","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"2145_CR34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M, Song A (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7(4):335\u2013345. https:\/\/doi.org\/10.1007\/s10456-004-8272-2","journal-title":"Angiogenesis"},{"issue":"1","key":"2145_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00417-015-2996-0","volume":"254","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Jiang Y, Bai Y, Wen J, Chen L (2016) Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab. Graefes Arch Clin Exp Ophthalmol 254(1):31\u201336. https:\/\/doi.org\/10.1007\/s00417-015-2996-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"2145_CR36","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, Shah V, Shah PS, Kelly EN (2016) Canadian neonatal network and the Canadian neonatal follow-up network investigators neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137(4):e20153218. https:\/\/doi.org\/10.1542\/peds.2015-3218","journal-title":"Pediatrics"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02145-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02145-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02145-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T17:34:41Z","timestamp":1653068081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02145-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2145"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02145-w","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"19 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has no commercial or proprietary interest. The authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was given; the relevant judgement S\u00fcleyman Demirel University, reference number is 17\/274.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}